Spotlight: October-November 2022
Updated: Dec 7, 2022
Words by Isabel O'Brien
GOLD looks back at some of the top news stories from the pharmaceutical industry over the last few months, covering major acquisitions, landmark trials, significant drug approvals and much more
05 October
Pfizer acquires Global Blood Therapeutics to advance sickle cell disease research
17 October
Moderna updates 2022 supply agreement with Gavi to secure variant-specific COVID-19 vaccines for 92 LMICs
18 October
Eli Lilly announces definitive agreement to acquire precision genetic medicine company Akouos
20 October
Takeda collaborates with Zedira and Dr Falk Pharma to develop first-in-class coeliac disease therapy
03 November
Pharma CEOs form first-of-its-kind task force to achieve emission reduction and net zero targets
09 November
Ipsen’s Onivyde for metastatic pancreatic cancer meets primary endpoints in Phase 3 trial
15 November
Access to Medicine Index 2022 reveals significant progress in access strategies, with GSK retaining the top spot
17 November
ABPI uses World Antibiotic Awareness Week to urge the pharma industry to develop new antibiotics
18 November
US anti-abortionists launch lawsuit to overturn FDA approval of abortion drug mifepristone
22 November
FDA approves Hemgenix, the first gene therapy to treat adults with haemophilia B
23 November
First-ever molecule targeting an RNA methyltransferase enzyme enters Phase I trial at STORM Therapeutics
24 November
Roche, Cancer Research UK and The University of Manchester begin multi-drug, precision medicine trial for rare cancers
This news round up features in GOLD 25 – read the full issue here.
